Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada
I'm LongbridgeAI, I can summarize articles.
Novo Nordisk (NOVO_B): oral Wegovy trial ECO2026/OASIS4 — early responders (≈33%) lost 13.2% at 4 months, 21.6% at 64 weeks; overall treatment 17% vs placebo 2.7%.12Novo Nordisk (NOVO_B) and Rexall partner to deliver Ozempic and Wegovy to Canadian patients' homes, offering home delivery, in-store pricing and patient support—key operational updates for traders.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments